| [1] |
Green DM, O′Donoghue K. A review of reproductive outcomes of women with two consecutive miscarriages and no living child[J]. J Obstet Gynaecol, 2019, 39(6): 816-821.DOI: 10.1080/01443615.2019.1576600.
|
| [2] |
|
| [3] |
Keller CC, Eikmans M, van der Hoorn MP, et al. Recurrent miscarriages and the association with regulatory T cells; A systematic review[J]. J Reprod Immunol, 2020, 139: 103105. DOI: 10.1016/j.jri.2020.103105.
|
| [4] |
Luo L, Zeng X, Huang Z, et al. Reduced frequency and functional defects of CD4 +CD25 high CD127 low/-regulatory T cells in patients with unexplained recurrent spontaneous abortion[J]. Reprod Biol Endocrinol, 2020, 18(1): 62. DOI: 10.1186/s12958-020-00619-7.
|
| [5] |
Liao J, Li Y, Li X, et al. Blood CD4 +CD25 + T regulatory cells constitute a potential predictive marker of subsequent miscarriage in unexplained recurrent pregnancy loss[J]. Int Immunopharmacol, 2022, 110: 108960. DOI: 10.1016/j.intimp.2022.108960.
|
| [6] |
Sarkesh A, Sorkhabi AD, Ahmadi H, et al. Allogeneic lymphocytes immunotherapy in female infertility: lessons learned and the road ahead[J]. Life Sci, 2022, 299: 120503. DOI： 10.1016/j.lfs.2022.120503.
|
| [7] |
Chen J, Liu B, Zhang Y, et al. Effect of immunotherapy on patients with unexplained recurrent spontaneous abortion[J]. Ann Palliat Med, 2020, 9(5): 2545-2550. DOI: 10.21037/apm-19-440b.
|
| [8] |
Liu S, Gu X, Weng R. Clinical effect of lymphocyte immunotherapy on patients with unexplained recurrent spontaneous abortion[J]. Immun Inflamm Dis, 2021, 9(4): 1272-1278. DOI: 10.1002/iid3.474.
|
| [9] |
Li J, Gu Y, Zhang S, et al. Effect of prepregnancy lymphocyte active immunotherapy on unexplained recurrent miscarriage, pregnancy success rate, and maternal-infant outcome[J]. Biomed Res Int, 2021, 2021: 7878752. DOI: 10.1155/2021/7878752.
|
| [10] |
Fainboim L, Belén S, González V, et al. Evaluation of paternal lymphocyte immunotherapy and potential biomarker mixed lymphocyte reaction-blocking factor in an argentinian cohort of women with unexplained recurrent spontaneous abortion and unexplained infertility[J]. Am J Reprod Immunol, 2021, 86(2): e13422. DOI: 10.1111/aji.13422.
|
| [11] |
Muyayalo KP, Li ZH, Mor G, et al. Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion[J]. Am J Reprod Immunol, 2018, 80(4): e13018. DOI: 10.1111/aji.13018.
|
| [12] |
Yamada H, Deguchi M, Saito S, et al. Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: a double-blind, randomised, placebo-controlled trial[J]. EClinicalMedicine, 2022, 50: 101527. DOI: 10.1016/j.eclinm.2022.101527.
|
| [13] |
Tang AW, Alfirevic Z, Turner MA, et al. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant[J]. Hum Reprod, 2013, 28(7)：1743-1752.DOI: 10.1093/humrep/det117.
|
| [14] |
Kolanska K, Dabi Y, Dechartres A, et al. Unexplained recurrent miscarriages: predictive value of immune biomarkers and immunomodulatory therapies for live birth[J]. Am J Reprod Immunol, 2021, 86(2): e13425. DOI: 10.1111/aji.13425.
|
| [15] |
Sun S, Li C, Kou X, et al. Association of prednisone and antinuclear antibodies with pregnancy outcomes in women with unexplained recurrent pregnancy loss[J]. Int J Gynaecol Obstet, 2021, 154(3): 492-499. DOI: 10.1002/ijgo.13556.
|
| [16] |
Ling Y, Huang Y, Chen C, et al. Low dose cyclosporin A treatment increases live birth rate of unexplained recurrent abortion - initial cohort study[J]. Clin Exp Obstet Gynecol, 2017, 44(2): 230-235.
|
| [17] |
Azizi R, Ahmadi M, Danaii S, et al. Cyclosporine A improves pregnancy outcomes in women with recurrent pregnancy loss and elevated Th1/Th2 ratio[J]. J Cell Physiol, 2019, 234(10): 19039-19047. DOI: 10.1002/jcp.28543.
|
| [18] |
Jerzak M, Ohams M, Górski A, et al. Etanercept immunotherapy in women with a history of recurrent reproductive failure[J]. Ginekol Pol, 2012, 83(4): 260-264.
|
| [19] |
Fu J, Li L, Qi L, et al. A randomized controlled trial of etanercept in the treatment of refractory recurrent spontaneous abortion with innate immune disorders[J]. Taiwan J Obstet Gynecol, 2019, 58(5): 621-625. DOI: 10.1016/j.tjog.2019.07.007.
|
| [20] |
Ding J, Wang J, Cai X et al. Granulocyte colony-stimulating factor in reproductive-related disease: function, regulation and therapeutic effect[J]. Biomed Pharmacother, 2022, 150: 112903. DOI: 10.1016/j.biopha.2022.112903.
|
| [21] |
Scarpellini F, Sbracia M. Use of granulocyte colony-stimulating factor for the treatment of unexplained recurrent miscarriage: a randomised controlled trial[J]. Hum Reprod, 2009, 24(11): 2703-2708. DOI: 10.1093/humrep/dep240.
|
| [22] |
Zafardoust S, Akhondi MM, Sadeghi MR, et al. Efficacy of intrauterine injection of granulocyte colony stimulating factor (G-CSF) on treatment of unexplained recurrent miscarriage: a pilot RCT study[J]. J Reprod Infertil, 2017, 18(4): 379-385.
|
| [23] |
Eapen A, Joing M, Kwon P, et al. Recombinant human granulocyte-colony stimulating factor in women with unexplained recurrent pregnancy losses: a randomized clinical trial[J]. Hum Reprod, 2019, 34(3): 424-432.DOI: 10.1093/humrep/dey393.
|
| [24] |
Coulam CB. Intralipid treatment for women with reproductive failures[J]. Am J Reprod Immunol, 2021, 85(4): e13290. DOI: 10.1111/aji.13290.
|
| [25] |
Plaçais L, Kolanska K, Kraiem YB, et al. Intralipid therapy for unexplained recurrent miscarriage and implantation failure: case-series and literature review[J]. Eur J Obstet Gynecol Reprod Biol, 2020, 252: 100-104. DOI: 10.1016/j.ejogrb.2020.06.017.
|
| [26] |
Kumar P, Marron K, Harrity C. Intralipid therapy and adverse reproductive outcome: is there any evidence？[J]. Reprod Fertil, 2021, 2(3): 173-186. DOI: 10.1530/raf-20-0052.
|
| [27] |
AbdulHussain G, Azizieh F, Makhseed M, et al. Effects of progesterone, dydrogesterone and estrogen on the production of Th1/Th2/Th17 cytokines by lymphocytes from women with recurrent spontaneous miscarriage[J]. J Reprod Immunol, 2020, 140: 103132. DOI: 10.1016/j.jri.2020.103132.
|
| [28] |
Saccone G, Schoen C, Franasiak JM, et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and Meta-analysis of randomized, controlled trials[J]. Fertil Steril, 2017, 107(2): 430.e3-438.e3. DOI: 10.1016/j.fertnstert.2016.10.031.
|
| [29] |
Rasmark Roepke E, Hellgren M, Hjertberg R, et al. Treatment efficacy for idiopathic recurrent pregnancy loss - a systematic review and Meta-analyses[J]. Acta Obstet Gynecol Scand, 2018, 97(8): 921-941. DOI: 10.1111/aogs.13352.
|
| [30] |
Haas DM, Hathaway TJ, Ramsey PS. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology[J]. Cochrane Database Syst Rev, 2019, 2019(11): CD003511. DOI: 10.1002/14651858.CD003511.pub5.
|
| [31] |
Voon HY, Sinthamoney E, Hamdan M, et al. Progestogens in the management of miscarriage and preterm birth[J]. Med J Malaysia, 2022, 77(4): 512-518.
|
| [32] |
de Jong PG, Kaandorp S, Di Nisio M, et al. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia[J]. Cochrane Database Syst Rev, 2014, 2014(7): CD004734. DOI: 10.1002/14651858.CD004734.pub4.
|
| [33] |
Yan X, Wang D, Yan P, et al. Low molecular weight heparin or LMWH plus aspirin in the treatment of unexplained recurrent miscarriage with negative antiphospholipid antibodies: a Meta-analysis of randomized controlled trial[J]. Eur J Obstet Gynecol Reprod Biol, 2022, 268: 22-30. DOI: 10.1016/j.ejogrb.2021.10.036.
|
| [34] |
Wang G, Zhang R, Li C, et al. Evaluation of the effect of low molecular weight heparin in unexplained recurrent pregnancy loss: a Meta-analysis of randomized controlled trials[J]. J Matern Fetal Neonatal Med, 2021, 35(25): 7601-7608. DOI: 10.1080/14767058.2021.1957819.
|
| [35] |
Li J, Gao YH, Xu L, et al. Meta-analysis of heparin combined with aspirin versus aspirin alone for unexplained recurrent spontaneous abortion[J]. Int J Gynaecol Obstet, 2020, 151(1): 23-32. DOI: 10.1002/ijgo.13266.
|
| [36] |
Grandone E, Tiscia GL, Mastroianno M, et al. Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry[J]. Hum Reprod, 2021, 36(8): 2083-2090. DOI: 10.1093/humrep/deab153.
|
| [37] |
Tamblyn JA, Pilarski NSP, Markland AD, et al. Vitamin D and miscarriage: a systematic review and Meta-analysis[J]. Fertil Steril, 2022, 118(1): 111-122. DOI: 10.1016/j.fertnstert.2022.04.017.
|
| [38] |
Gao J, Wang L, Bu L, et al. Immunopharmacological properties of itD3: 1, 25VitD3 modulates regulatory T cells and Th17 cells and the cytokine balance in PBMCs from women with unexplained recurrent spontaneous abortion (URSA)[J]. Curr Mol Pharmacol, 2022, 15(5): 779-793. DOI: 10.2174/1874467214666211015084803.
|
| [39] |
Li L, Dou L, Leung PC, et al. Chinese herbal medicines for unexplained recurrent miscarriage[J]. Cochrane Database Syst Rev, 2016, 2016(1): CD010568. DOI: 10.1002/14651858.CD010568.pub2.
|
| [40] |
Shigemi D, Hashimoto Y, Michihata N, et al. Effect of Japanese herbal kampo medicines on live birth rate in women with recurrent pregnancy loss[J]. Int J Gynaecol Obstet, 2021, 153(3): 489-495. DOI: 10.1002/ijgo.13477.
|
| [41] |
Liu XY, Fan Q, Wang J, et al. Higher chromosomal abnormality rate in blastocysts from young patients with idiopathic recurrent pregnancy loss[J]. Fertil Steril, 2020, 113(4): 853-864. DOI: 10.1016/j.fertnstert.2019.11.016.
|
| [42] |
Cao M, Zhang Q, Zhou W, et al. Analysis of aneuploidy rate and pregnancy outcomes in unexplained recurrent pregnancy loss couples with chromosome polymorphism after PGT-A[J]. Front Med (Lausanne), 2022, 9: 803988. DOI: 10.3389/fmed.2022.803988.
|
| [43] |
Wang J, Yang J, Yan Y, et al. Effect of adoptive transfer of CD4 +CD25 +Foxp3 + Treg induced by trichostatin A on the prevention of spontaneous abortion[J]. J Reprod Immunol, 2019, 131: 30-35. DOI: 10.1016/j.jri.2018.12.002.
|
| [44] |
Zhang D, Lin Y, Li Y, et al. Mesenchymal stem cells enhance Treg immunosuppressive function at the fetal-maternal interface[J]. J Reprod Immunol, 2021, 148: 103366. DOI: 10.1016/j.jri.2021.103366.
|